RESPOND STUDY

PROVEN REAL-WORLD EFFECTIVENESS WITH PURAPLY® AM

The largest real-world effectiveness study demonstrating that PuraPly AM supports healing and aids in granulation tissue formation[1]

THE STUDY

N=307
28 Sites
Prospective, multicenter cohort study[1]

Large Difficult-to-Heal Wounds
12.9 cm^2 mean wound area[1]

THE RESULTS

86% of wounds demonstrated improvement in wound bed conditions[1]

- Increased granulation tissue
- Reduced exudate
- Readiness for other advanced skin substitutes

BASELINE DATA & WOUND TYPES TREATED[1]

Mean patient age	70.3 years	Venous leg ulcers	67
Mean wound duration	96.2 days	Diabetic foot ulcers	62
Mean wound depth	5.2 mm	Pressure ulcers	45
Mean wound volume	11.2 cm^3	Post-surgical wounds	54
Mean # of applications*	5.2	Other wounds	79

*Patients received standard of care in addition to PuraPly AM over a 32-week study period

PURAPLY® AM SUPPORTED HEALING IN CHALLENGING WOUNDS

REDUCTION IN WOUND AREA, DEPTH, AND VOLUME

81%
of wounds achieved
> 60% reduction in area[1,*]



71%
of wounds achieved
> 60% reduction in depth[1,*]

85%
of wounds achieved
> 75% reduction in volume[1,*]

*At 32 weeks

RATES OF WOUND CLOSURE

41.5%
of wounds achieved
complete closure at 12 weeks[1]

17 WEEKS
Median time to closure
for all wounds[1]

Frequency of wound closure; all wounds (N=307)



Median time to wound closure by wound type



Control bioburden, support healing, and aid in granulation tissue formation with PuraPly AM[1-4]

Reference: 1. Bain MA, et al. *J Comp Eff Res.* 2020;9(10):691-703. **2.** Davis SC, et al. *Int Wound J.* 2022;19(1):86-99. **3.** Brantley J, et al. *Wounds Int.* 2016;7(3):1-5. **4.** Data on file. PDR-0008. Organogenesis Inc.

ORGANOGENESIS
PuraPly® AM
Antimicrobial Wound Matrix